The global painkillers market is expected to enjoy a valuation of US$ 70.0 Billion by the end of the year 2023, and further expand at a CAGR of 3.7% to reach a valuation of ~US$ 100.9 Billion by the year 2033. According to a recent study by Future Market Insights, opioids are leading the market with a share of about 53.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 67.7 Billion |
| Market Value 2023 | US$ 70.0 Billion |
| Market Value 2033 | US$ 100.9 Billion |
| CAGR 2023 to 2032 | 3.7% |
| Market Share of Top 5 Countries (2022) | 59.1% |
| Key Market Players | AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., Boehringer Ingelheim International GmbH, Pfizer Inc., Zydus Lifesciences Ltd. (Cadila Pharmaceuticals), GSK plc., Abbott Laboratories, Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Procter & Gamble, AstraZeneca, Cardinal Health, Perrigo Company Plc., Bausch Health Companies Inc., Viatris, Amneal Pharmaceuticals, and Purdue Pharmaceuticals L.P. |
Manufacturers are focused on developing non-opioid drugs with a novel extended-release delivery approach that can relieve postoperative pain over a longer period of time. Opioid drugs are highly effective pain relievers, but they are also highly addictive and can lead to abuse and dependence. The opioid epidemic has led to a growing need for non-opioid pain management options.
Overall, the development of non-opioid extended-release pain medications is an important step in addressing the opioid epidemic and providing patients with a safer option, thereby will drive the overall growth of the painkillers market during the forecast period (2023 to 2033).
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for painkillers was around 4.8% of the overall ~US$ 1,400.5 Billion of the global pharmaceuticals market in 2022.
An increasing number of patients suffering from chronic diseases such as cancer and chronic obstructive pulmonary disease (COPD), various prescription drugs for postoperative pain management, and various traumas leading to pain are expected to fuel the growth of global market for painkillers.
Certain health conditions such as diabetes, cancer, and autoimmune diseases are known to increase the risk of developing chronic pain and neuropathic pain. Therefore, it is important that healthcare providers are aware of the increasing prevalence of these conditions and provide appropriate treatment strategies to improve patients’ quality of life.
Overall, the global market is projected to expand at a CAGR of 3.7% during the forecast period (2023 to 2033).
The regulatory scenario for painkillers can have a significant impact on the growth of the market. In recent years, opioid pain medications have come under increased scrutiny, resulting in stricter regulations and restrictions on their use. This has created opportunities for non-opioid pain medications such as NSAIDs and other non-narcotic medications to gain market share. In addition, regulatory initiatives to improve pain management and reduce opioid abuse, such as prescription drug monitoring programs and physician education programs, may create opportunities for companies offering alternative pain management solutions.
Overall, the regulatory scenario for painkillers is complex and evolving. However, regulatory initiatives that promote safe and effective pain management can create growth opportunities for the painkillers manufacturers, especially for companies that offer innovative solutions.
The companies that navigate the regulatory landscape and invest in innovative solutions to meet the evolving needs of patients and healthcare providers offer lucrative growth opportunities for the market and will raise the market to new heights during the forecast period from 2023 to 2033.
Principal Consultant
Per capita use of opioids is low in Asian countries. According to the Global Opioids Policy Initiative (GOPI), some of the main factors responsible for low opioid use in Asia and Africa include: full patient cost coverage is required, patient registration required before prescribing opioids, and physicians must obtain special permission to prescribe opioids.
The availability of painkillers in Asian and African countries may have a significant impact on the growth of the painkiller market in these regions. In many of these countries, access to painkillers is limited due to various factors such as lack of infrastructure, regulatory issues, and economic constraints. This can lead to a significant unmet need for painkillers, which can ultimately impact the growth of the market.
These factors are negatively impacting the growth of the painkillers market in Asia and Africa and projections have been made which are restraining the growth of the market during the forecast period from 2023 to 2033 in the world.
With a market share of 91.5% in 2022, the USA will continue to dominate the North American region. This large market share is expected to continue throughout the forecast period.
In the USA, palliative care facilities are provided in accordance with government and commercial reimbursement guidelines. Palliative care programs in hospitals in the USA include dedicated inpatient palliative care units and palliative care consultation teams.
Also, the American Chronic Pain Association has designated September as Pain Awareness Month, and more than 80 organizations and healthcare professionals, and consumer groups have supported the initiative. This will result in the propulsion of demand for painkillers in the country during the forecast period of 2023 to 2033.
Germany dominates the Western European region with a total market share of about 25.6% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
In Germany, there is a growing interest in personalized medicine, which is also reflected in the painkillers market. Pharmaceutical companies are developing painkillers tailored to specific patient groups, such as the elderly or people with kidney problems, in order to achieve more targeted and effective pain relief. This will foster profitable market growth over the course of the forecast period.
Japan dominates the East Asia region with market share of 45.1% in 2022 and will expand with growing numbers in the future.
Japan has taken various initiatives to improve pain management, including the establishment of pain clinics, the development of clinical guidelines for pain management, and the training of healthcare professionals in pain management.
The Japan market for painkillers is expected to continue to grow in the coming years, driven by changing demographics, shifting consumer preferences, and increasing investment in pain management R&D all suggest that Japan will continue to be an important market for painkillers.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Opioids are expected to present growth at a CAGR of 2.1% throughout the forecast period, with a market share of 53.4% in the global market in 2022.
Opioids are relatively inexpensive compared to some of the newer non-opioid pain medications. Opioids have been used for pain relief for centuries, and many healthcare providers are familiar with their use and feel comfortable prescribing them.
As the demand for non-opioids continues to grow, the market for painkillers is expected to expand significantly in the coming years.
Prescription Drugs dominated the global market with a value share of 58.8% in 2022.
Prescription drugs are leading in the global market for painkillers over over-the-counter (OTC) drugs because they are often more effective at providing pain relief for moderate to severe pain. Prescription painkillers are also often covered by health insurance, which can make them more affordable for patients who need them.
Surgical pain is leading the market with a market share of 43.3% in the global market in 2022.
Surgical pain is leading in the market over other indications because surgery is a common cause of acute pain, and pain relief is an important part of the post-surgical recovery process. Many surgical procedures can be painful, and without adequate pain control, patients may experience significant discomfort, which can delay healing and recovery.
The oral route of administration is leading the market with a revenue share of 38.7% in 2022 as oral painkillers are easy to take and can be self-administered, which can make them more convenient for patients and also it is generally less invasive than other routes, such as injections or transdermal patches, which can make it more appealing for patients.
Retail pharmacies hold a market share value of 27.5% during the year 2022. Retail pharmacies typically stock a wide range of painkillers, including both prescription and over-the-counter options and they are easily accessible to consumers, which makes it convenient for them to purchase painkillers.
Key market players in the painkillers market launch their products. This promotional strategy is expected to be highly impactful to enter into the market.
A few of the recent instances include
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Painkillers market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Western Europe, Eastern Europe, Russia & Belarus, Balkan & Baltic Countries, South Asia & Pacific, East Asia, Central Asia, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Spain, France, BENELUX, Nordic Countries, Poland, Hungary, Czech Republic, Romania, Russia and Belarus, Balkan & Baltic Countries, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Japan, China, South Korea, Central Asia, Australia and New Zealand, Türkiye, GCC Countries, Kingdom of Saudi Arabia, Israel, North Africa, and South Africa |
| Key Market Segments Covered | Drug Class, Product, Indication, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The painkillers market is expected to reach a valuation of at US$ 70.0 billion in 2023.
AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., are leading painkillers industry players.
Opioids are the key segment by drug class in the worldwide painkillers market.
Over the historical period, from 2018 to 2022, the painkillers market registered a 2.9% CAGR.
North America painkillers market is expected to hold a 92.2% share in 2023.
1. Executive Summary | Painkillers Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value Added Insights
4.1. Patient Treatment Journey
4.2. Disease Epidemiology
4.3. Standard daily doses per 100,000 people, By Countries
4.4. Trends in Use of Prescription Opioids
4.5. Annual Mean Consumption of Controlled Opioids
4.6. Changes in Drug Overdose Deaths in USA, 2019 to 2020
4.7. Overdose Death Rates Involving Opioids, By Type, USA, 1999 to 2020
4.8. Total Opioid Prescriptions Dispensed and Opioid Dispensing Rate per 100 People
4.9. Number of Prescription, By Drug Class, Indication and Route of Administration
4.10. Commercial Scope of Opioids and Abuse Deterrent Technologies (ADT)
4.11. Approved Extended-release and Long-acting (ER/LA) Opioids with Abuse-deterrent Properties
4.12. Abuse Deterrent Opioid Formulation Status
4.13. Top 20 most commonly used NSAIDs
4.14. Percentage of Individual NSAID Usage and Prescription of NSAIDs by Different Indications
4.15. Pipeline Assessment
4.15.1. By Drug Class
4.15.2. Comprehensive Assessment by Phases
4.15.3. Emerging Novel trends
4.15.4. Late-stage Pipeline Drugs Assessment
4.16. List of Key Players, By Region
4.17. Key Regulations
4.18. Reimbursement Landscape
4.19. PESTLE Analysis
4.20. Porter’s Analysis
4.21. Value chain analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Life Expectancy Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Increasing Treatment Seeking Rate
5.2.3. Healthcare Bodies Advocating Adoption of Combat Methodological Approach
5.2.4. Increasing Aging Population
5.2.5. Patent Expiration of Novel Pain Management Drugs (Opioids)
5.2.6. Introduction of Novel Abuse-deterrent Pain Management Drugs
5.2.7. Average Annual Spending on Pain Management Drugs
5.2.8. Awareness for Pain Management Drugs
5.2.9. Popularity of Generic Products
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. Current COVID-19 Statistics and Probable Future Impact
6.2. COVID-19 and Impact Analysis
6.2.1. By Drug Class
6.2.2. By Product
6.2.3. By Indication
6.2.4. By Route of Administration
6.2.5. By Distribution Channel
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis 2018 to2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2018 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
8.3.1. Opioids
8.3.1.1. Tramadol
8.3.1.2. Oxycodone
8.3.1.3. Hydrocodone
8.3.1.4. Other Opioids
8.3.2. NSAIDs
8.3.3. Local Anesthetics
8.3.4. Acetaminophen
8.4. Market Attractiveness Analysis By Drug Class
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Product, 2018 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033
9.3.1. Over-The-Counter (OTC) Products
9.3.2. Prescription Drugs
9.4. Market Attractiveness Analysis By Product
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
10.3.1. Surgical Pain
10.3.2. Cancer Pain
10.3.3. Neuropathic Pain
10.3.4. Musculoskeletal & Joint Pain
10.3.5. Others
10.4. Market Attractiveness Analysis By Indication
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2018 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
11.3.1. Injectable
11.3.2. Oral
11.3.3. Rectal
11.3.4. Topical
11.3.5. Transdermal
11.3.6. Others
11.4. Market Attractiveness Analysis By Route of Administration
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By Distribution Channel , 2018 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
12.3.1. Hospital Pharmacies
12.3.2. Specialty Clinics
12.3.3. Long Term Care Centers
12.3.4. Retail pharmacies
12.3.5. Drug Stores
12.3.6. Online Pharmacies
12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region
13.1. Introduction Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022
13.2. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
13.2.1. North America
13.2.2. Latin America
13.2.3. Western Europe
13.2.4. Eastern Europe
13.2.5. Russia & Belarus
13.2.6. Balkan & Baltic Countries
13.2.7. South Asia & Pacific
13.2.8. East Asia
13.2.9. Central Asia
13.2.10. Middle East & Africa
13.3. Market Attractiveness Analysis By Region
14. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Drug Class
14.3.3. By Product
14.3.4. By Indication
14.3.5. By Route of Administration
14.3.6. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Product
14.4.4. By Indication
14.4.5. By Route of Administration
14.4.6. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. USA Market
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Drug Class
14.7.1.2.2. By Product
14.7.1.2.3. By Indication
14.7.1.2.4. By Route of Administration
14.7.1.2.5. By Distribution Channel
14.7.2. Canada Market
14.7.3. Introduction
14.7.4. Market Analysis and Forecast by Market Taxonomy
14.7.4.1.1. By Drug Class
14.7.4.1.2. By Product
14.7.4.1.3. By Indication
14.7.4.1.4. By Route of Administration
14.7.4.1.5. By Distribution Channel
15. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Drug Class
15.3.3. By Product
15.3.4. By Indication
15.3.5. By Route of Administration
15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Class
15.4.3. By Product
15.4.4. By Indication
15.4.5. By Route of Administration
15.4.6. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Brazil Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Drug Class
15.7.1.2.2. By Product
15.7.1.2.3. By Indication
15.7.1.2.4. By Route of Administration
15.7.1.2.5. By Distribution Channel
15.7.2. Mexico Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Drug Class
15.7.2.2.2. By Product
15.7.2.2.3. By Indication
15.7.2.2.4. By Route of Administration
15.7.2.2.5. By Distribution Channel
15.7.3. Argentina Market
15.7.4. Introduction
15.7.5. Market Analysis and Forecast by Market Taxonomy
15.7.5.1.1. By Drug Class
15.7.5.1.2. By Product
15.7.5.1.3. By Indication
15.7.5.1.4. By Route of Administration
15.7.5.1.5. By Distribution Channel
16. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. France
16.3.1.3. Spain
16.3.1.4. Italy
16.3.1.5. BENELUX
16.3.1.6. Nordic Countries
16.3.1.7. United kingdom
16.3.2. By Drug Class
16.3.3. By Product
16.3.4. By Indication
16.3.5. By Route of Administration
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Product
16.4.4. By Indication
16.4.5. By Route of Administration
16.4.6. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. Germany Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Drug Class
16.7.1.2.2. By Product
16.7.1.2.3. By Indication
16.7.1.2.4. By Route of Administration
16.7.1.2.5. By Distribution Channel
16.7.2. France Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Drug Class
16.7.2.2.2. By Product
16.7.2.2.3. By Indication
16.7.2.2.4. By Route of Administration
16.7.2.2.5. By Distribution Channel
16.7.3. Spain Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Drug Class
16.7.3.2.2. By Product
16.7.3.2.3. By Indication
16.7.3.2.4. By Route of Administration
16.7.3.2.5. By Distribution Channel
16.7.4. Italy Market
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Drug Class
16.7.4.2.2. By Product
16.7.4.2.3. By Indication
16.7.4.2.4. By Route of Administration
16.7.4.2.5. By Distribution Channel
16.7.5. BENELUX Market
16.7.5.1. Introduction
16.7.5.2. Market Analysis and Forecast by Market Taxonomy
16.7.5.2.1. By Drug Class
16.7.5.2.2. By Product
16.7.5.2.3. By Indication
16.7.5.2.4. By Route of Administration
16.7.5.2.5. By Distribution Channel
16.7.6. Nordic Countries Market
16.7.6.1. Introduction
16.7.6.2. Market Analysis and Forecast by Market Taxonomy
16.7.6.2.1. By Drug Class
16.7.6.2.2. By Product
16.7.6.2.3. By Indication
16.7.6.2.4. By Route of Administration
16.7.6.2.5. By Distribution Channel
16.7.7. United kingdom Market
16.7.7.1. Introduction
16.7.7.2. Market Analysis and Forecast by Market Taxonomy
16.7.7.2.1. By Drug Class
16.7.7.2.2. By Product
16.7.7.2.3. By Indication
16.7.7.2.4. By Route of Administration
16.7.7.2.5. By Distribution Channel
17. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1.1. Poland
17.3.1.1.2. Hungary
17.3.1.1.3. Romania
17.3.1.1.4. Czech Republic
17.3.1.1.5. Rest of Eastern Europe
17.3.2. By Drug Class
17.3.3. By Product
17.3.4. By Indication
17.3.5. By Route of Administration
17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Product
17.4.4. By Indication
17.4.5. By Route of Administration
17.4.6. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. Poland Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Drug Class
17.7.1.2.2. By Product
17.7.1.2.3. By Indication
17.7.1.2.4. By Route of Administration
17.7.1.2.5. By Distribution Channel
17.7.2. Hungary Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Drug Class
17.7.2.2.2. By Product
17.7.2.2.3. By Indication
17.7.2.2.4. By Route of Administration
17.7.2.2.5. By Distribution Channel
17.7.3. Romania Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Drug Class
17.7.3.2.2. By Product
17.7.3.2.3. By Indication
17.7.3.2.4. By Route of Administration
17.7.3.2.5. By Distribution Channel
17.7.4. Czech Republic Market
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Drug Class
17.7.4.2.2. By Product
17.7.4.2.3. By Indication
17.7.4.2.4. By Route of Administration
17.7.4.2.5. By Distribution Channel
18. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. I India
18.3.1.2. Indonesia
18.3.1.3. Thailand
18.3.1.4. Philippines
18.3.1.5. Malaysia
18.3.1.6. Vietnam
18.3.1.7. Rest of South Asia
18.3.1.8. Australia & New Zealand
18.3.2. By Drug Class
18.3.3. By Product
18.3.4. By Indication
18.3.5. By Route of Administration
18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Class
18.4.3. By Product
18.4.4. By Indication
18.4.5. By Route of Administration
18.4.6. By Distribution Channel
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. India Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Drug Class
18.7.1.2.2. By Product
18.7.1.2.3. By Indication
18.7.1.2.4. By Route of Administration
18.7.1.2.5. By Distribution Channel
18.7.2. Indonesia Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Drug Class
18.7.2.2.2. By Product
18.7.2.2.3. By Indication
18.7.2.2.4. By Route of Administration
18.7.2.2.5. By Distribution Channel
18.7.3. Thailand Market
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Drug Class
18.7.3.2.2. By Product
18.7.3.2.3. By Indication
18.7.3.2.4. By Route of Administration
18.7.3.2.5. By Distribution Channel
18.7.4. Philippines Market
18.7.4.1. Introduction
18.7.4.2. Market Analysis and Forecast by Market Taxonomy
18.7.4.2.1. By Drug Class
18.7.4.2.2. By Product
18.7.4.2.3. By Indication
18.7.4.2.4. By Route of Administration
18.7.4.2.5. By Distribution Channel
18.7.5. Malaysia Market
18.7.5.1. Introduction
18.7.5.2. Market Analysis and Forecast by Market Taxonomy
18.7.5.2.1. By Drug Class
18.7.5.2.2. By Product
18.7.5.2.3. By Indication
18.7.5.2.4. By Route of Administration
18.7.5.2.5. By Distribution Channel
18.7.6. Vietnam Market
18.7.6.1. Introduction
18.7.6.2. Market Analysis and Forecast by Market Taxonomy
18.7.6.2.1. By Drug Class
18.7.6.2.2. By Product
18.7.6.2.3. By Indication
18.7.6.2.4. By Route of Administration
18.7.6.2.5. By Distribution Channel
18.7.7. Australia & New Zealand Market
18.7.7.1. Introduction
18.7.7.2. Market Analysis and Forecast by Market Taxonomy
18.7.7.2.1. By Drug Class
18.7.7.2.2. By Product
18.7.7.2.3. By Indication
18.7.7.2.4. By Route of Administration
18.7.7.2.5. By Distribution Channel
19. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Japan
19.3.1.2. China
19.3.1.3. South Korea
19.3.2. By Drug Class
19.3.3. By Product
19.3.4. By Indication
19.3.5. By Route of Administration
19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Class
19.4.3. By Product
19.4.4. By Indication
19.4.5. By Route of Administration
19.4.6. By Distribution Channel
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. Japan Market
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Drug Class
19.7.1.2.2. By Product
19.7.1.2.3. By Indication
19.7.1.2.4. By Route of Administration
19.7.1.2.5. By Distribution Channel
19.7.2. China Market
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Drug Class
19.7.2.2.2. By Product
19.7.2.2.3. By Indication
19.7.2.2.4. By Route of Administration
19.7.2.2.5. By Distribution Channel
19.7.3. South Korea Market
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Drug Class
19.7.3.2.2. By Product
19.7.3.2.3. By Indication
19.7.3.2.4. By Route of Administration
19.7.3.2.5. By Distribution Channel
20. Central Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Drug Class
20.3.2. By Product
20.3.3. By Indication
20.3.4. By Route of Administration
20.3.5. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Drug Class
20.4.2. By Product
20.4.3. By Indication
20.4.4. By Route of Administration
20.4.5. By Distribution Channel
20.5. Market Trends
20.6. Drivers and Restraints - Impact Analysis
21. Russia & Belarus Market Analysis 2018 to 2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Drug Class
21.3.2. By Product
21.3.3. By Indication
21.3.4. By Route of Administration
21.3.5. By Distribution Channel
21.4. Market Attractiveness Analysis
21.4.1. By Drug Class
21.4.2. By Product
21.4.3. By Indication
21.4.4. By Route of Administration
21.4.5. By Distribution Channel
21.5. Market Trends
21.6. Drivers and Restraints - Impact Analysis
22. Balkan & Baltic Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033
22.1. Introduction
22.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
22.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
22.3.1. By Drug Class
22.3.2. By Product
22.3.3. By Indication
22.3.4. By Route of Administration
22.3.5. By Distribution Channel
22.4. Market Attractiveness Analysis
22.4.1. By Drug Class
22.4.2. By Product
22.4.3. By Indication
22.4.4. By Route of Administration
22.4.5. By Distribution Channel
22.5. Market Trends
22.6. Drivers and Restraints - Impact Analysis
23. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
23.1. Introduction
23.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022
23.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
23.3.1. By Country
23.3.1.1. GCC Countries
23.3.1.2. Kingdom of Saudi Arabia
23.3.1.3. Türkiye
23.3.1.4. Northern Africa
23.3.1.5. South Africa
23.3.1.6. Israel
23.3.2. By Drug Class
23.3.3. By Product
23.3.4. By Indication
23.3.5. By Route of Administration
23.3.6. By Distribution Channel
23.4. Market Attractiveness Analysis
23.4.1. By Country
23.4.2. By Drug Class
23.4.3. By Product
23.4.4. By Indication
23.4.5. By Route of Administration
23.4.6. By Distribution Channel
23.5. Market Trends
23.6. Drivers and Restraints - Impact Analysis
23.7. Country Level Analysis & Forecast
23.7.1. GCC Countries Market
23.7.1.1. Introduction
23.7.1.2. Market Analysis and Forecast by Market Taxonomy
23.7.1.2.1. By Drug Class
23.7.1.2.2. By Product
23.7.1.2.3. By Indication
23.7.1.2.4. By Route of Administration
23.7.1.2.5. By Distribution Channel
23.7.2. Kingdom of Saudi Arabia Market
23.7.2.1. Introduction
23.7.2.2. Market Analysis and Forecast by Market Taxonomy
23.7.2.2.1. By Drug Class
23.7.2.2.2. By Product
23.7.2.2.3. By Indication
23.7.2.2.4. By Route of Administration
23.7.2.2.5. By Distribution Channel
23.7.3. Türkiye Market
23.7.3.1. Introduction
23.7.3.2. Market Analysis and Forecast by Market Taxonomy
23.7.3.2.1. By Drug Class
23.7.3.2.2. By Product
23.7.3.2.3. By Indication
23.7.3.2.4. By Route of Administration
23.7.3.2.5. By Distribution Channel
23.7.4. Northern Africa Market
23.7.4.1. Introduction
23.7.4.2. Market Analysis and Forecast by Market Taxonomy
23.7.4.2.1. By Drug Class
23.7.4.2.2. By Product
23.7.4.2.3. By Indication
23.7.4.2.4. By Route of Administration
23.7.4.2.5. By Distribution Channel
23.7.5. South Africa Market
23.7.5.1. Introduction
23.7.5.2. Market Analysis and Forecast by Market Taxonomy
23.7.5.2.1. By Drug Class
23.7.5.2.2. By Product
23.7.5.2.3. By Indication
23.7.5.2.4. By Route of Administration
23.7.5.2.5. By Distribution Channel
23.7.6. Israel Market
23.7.6.1. Introduction
23.7.6.2. Market Analysis and Forecast by Market Taxonomy
23.7.6.2.1. By Drug Class
23.7.6.2.2. By Product
23.7.6.2.3. By Indication
23.7.6.2.4. By Route of Administration
23.7.6.2.5. By Distribution Channel
24. Market Structure Analysis
24.1. Market Analysis by Tier of Companies
24.2. Market Share Analysis of Top Players (%), 2020-2033
24.3. Market Share Analysis, 2022
24.4. Brand Share Analysis of Acetaminophen Market, 2022
25. Competition Analysis
25.1. Competition Dashboard
25.2. Competition Benchmarking
25.3. Key Development Analysis
25.4. Branding and Promotional Strategies
25.5. Competition Deep Dive
25.5.1. AbbVie Inc. (Allergan plc)
25.5.1.1. Overview
25.5.1.2. Product Portfolio
25.5.1.3. Sales Footprint
25.5.1.4. Key Financials
25.5.1.5. Key Developments
25.5.1.6. Strategy Overview
25.5.1.7. SWOT Analysis
25.5.2. Bristol Myers Squibb Co.
25.5.2.1. Overview
25.5.2.2. Product Portfolio
25.5.2.3. Sales Footprint
25.5.2.4. Key Financials
25.5.2.5. Key Developments
25.5.2.6. Strategy Overview
25.5.2.7. SWOT Analysis
25.5.3. Sanofi S.A.
25.5.3.1. Overview
25.5.3.2. Product Portfolio
25.5.3.3. Sales Footprint
25.5.3.4. Key Financials
25.5.3.5. Key Developments
25.5.3.6. Strategy Overview
25.5.3.7. SWOT Analysis
25.5.4. Boehringer Ingelheim International GmbH
25.5.4.1. Overview
25.5.4.2. Product Portfolio
25.5.4.3. Sales Footprint
25.5.4.4. Key Financials
25.5.4.5. Key Developments
25.5.4.6. Strategy Overview
25.5.4.7. SWOT Analysis
25.5.5. Pfizer Inc.
25.5.5.1. Overview
25.5.5.2. Product Portfolio
25.5.5.3. Sales Footprint
25.5.5.4. Key Financials
25.5.5.5. Key Developments
25.5.5.6. Strategy Overview
25.5.5.7. SWOT Analysis
25.5.6. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)
25.5.6.1. Overview
25.5.6.2. Product Portfolio
25.5.6.3. Sales Footprint
25.5.6.4. Key Financials
25.5.6.5. Key Developments
25.5.6.6. Strategy Overview
25.5.6.7. SWOT Analysis
25.5.7. GSK plc.
25.5.7.1. Overview
25.5.7.2. Product Portfolio
25.5.7.3. Sales Footprint
25.5.7.4. Key Financials
25.5.7.5. Key Developments
25.5.7.6. Strategy Overview
25.5.7.7. SWOT Analysis
25.5.8. Abbott Laboratories, Inc.
25.5.8.1. Overview
25.5.8.2. Product Portfolio
25.5.8.3. Sales Footprint
25.5.8.4. Key Financials
25.5.8.5. Key Developments
25.5.8.6. Strategy Overview
25.5.8.7. SWOT Analysis
25.5.9. Novartis AG
25.5.9.1. Overview
25.5.9.2. Product Portfolio
25.5.9.3. Sales Footprint
25.5.9.4. Key Financials
25.5.9.5. Key Developments
25.5.9.6. Strategy Overview
25.5.9.7. SWOT Analysis
25.5.10. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
25.5.10.1. Overview
25.5.10.2. Product Portfolio
25.5.10.3. Sales Footprint
25.5.10.4. Key Financials
25.5.10.5. Key Developments
25.5.10.6. Strategy Overview
25.5.10.7. SWOT Analysis
25.5.11. Sun Pharmaceutical Industries Ltd.
25.5.11.1. Overview
25.5.11.2. Product Portfolio
25.5.11.3. Sales Footprint
25.5.11.4. Key Financials
25.5.11.5. Key Developments
25.5.11.6. Strategy Overview
25.5.11.7. SWOT Analysis
25.5.12. Teva Pharmaceuticals Ltd.
25.5.12.1. Overview
25.5.12.2. Product Portfolio
25.5.12.3. Sales Footprint
25.5.12.4. Key Financials
25.5.12.5. Key Developments
25.5.12.6. Strategy Overview
25.5.12.7. SWOT Analysis
25.5.13. Mallinckrodt Pharmaceuticals
25.5.13.1. Overview
25.5.13.2. Product Portfolio
25.5.13.3. Sales Footprint
25.5.13.4. Key Financials
25.5.13.5. Key Developments
25.5.13.6. Strategy Overview
25.5.13.7. SWOT Analysis
25.5.14. Endo Pharmaceuticals Inc.
25.5.14.1. Overview
25.5.14.2. Product Portfolio
25.5.14.3. Sales Footprint
25.5.14.4. Key Financials
25.5.14.5. Key Developments
25.5.14.6. Strategy Overview
25.5.14.7. SWOT Analysis
25.5.15. Bayer AG
25.5.15.1. Overview
25.5.15.2. Product Portfolio
25.5.15.3. Sales Footprint
25.5.15.4. Key Financials
25.5.15.5. Key Developments
25.5.15.6. Strategy Overview
25.5.15.7. SWOT Analysis
25.5.16. F. Hoffmann-La Roche Ltd.
25.5.16.1. Overview
25.5.16.2. Product Portfolio
25.5.16.3. Sales Footprint
25.5.16.4. Key Financials
25.5.16.5. Key Developments
25.5.16.6. Strategy Overview
25.5.16.7. SWOT Analysis
25.5.17. Procter & Gamble
25.5.17.1. Overview
25.5.17.2. Product Portfolio
25.5.17.3. Sales Footprint
25.5.17.4. Key Financials
25.5.17.5. Key Developments
25.5.17.6. Strategy Overview
25.5.17.7. SWOT Analysis
25.5.18. AstraZeneca
25.5.18.1. Overview
25.5.18.2. Product Portfolio
25.5.18.3. Sales Footprint
25.5.18.4. Key Financials
25.5.18.5. Key Developments
25.5.18.6. Strategy Overview
25.5.18.7. SWOT Analysis
25.5.19. Cardinal Health
25.5.19.1. Overview
25.5.19.2. Product Portfolio
25.5.19.3. Sales Footprint
25.5.19.4. Key Financials
25.5.19.5. Key Developments
25.5.19.6. Strategy Overview
25.5.19.7. SWOT Analysis
25.5.20. Perrigo Company Plc.
25.5.20.1. Overview
25.5.20.2. Product Portfolio
25.5.20.3. Sales Footprint
25.5.20.4. Key Financials
25.5.20.5. Key Developments
25.5.20.6. Strategy Overview
25.5.20.7. SWOT Analysis
25.5.21. Bausch Health Companies Inc.
25.5.21.1. Overview
25.5.21.2. Product Portfolio
25.5.21.3. Sales Footprint
25.5.21.4. Key Financials
25.5.21.5. Key Developments
25.5.21.6. Strategy Overview
25.5.21.7. SWOT Analysis
25.5.22. Viatris
25.5.22.1. Overview
25.5.22.2. Product Portfolio
25.5.22.3. Sales Footprint
25.5.22.4. Key Financials
25.5.22.5. Key Developments
25.5.22.6. Strategy Overview
25.5.22.7. SWOT Analysis
25.5.23. AMillioneal Pharmaceuticals
25.5.23.1. Overview
25.5.23.2. Product Portfolio
25.5.23.3. Sales Footprint
25.5.23.4. Key Financials
25.5.23.5. Key Developments
25.5.23.6. Strategy Overview
25.5.23.7. SWOT Analysis
25.5.24. Purdue Pharmaceuticals L.P.
25.5.24.1. Overview
25.5.24.2. Product Portfolio
25.5.24.3. Sales Footprint
25.5.24.4. Key Financials
25.5.24.5. Key Developments
25.5.24.6. Strategy Overview
25.5.24.7. SWOT Analysis
26. Assumptions and Acronyms Used
27. Research Methodology
Explore Healthcare Insights
View Reports
Painkillers Market
